
Perry Baromedical
Multiplace Series
$150,000 - $400,000+
An honest look at the evidence, what the Lyme community reports, and what pressure levels matter.
Hyperbaric oxygen therapy (HBOT) for Lyme Disease has limited clinical evidence. This is currently an off-label use and is not covered by insurance. The recommended protocol is 2.0–2.4 ATA ATA for 60–90 minutes per session per session over 20–40 sessions sessions.
Key Takeaways
Lyme disease, caused by the spirochete Borrelia burgdorferi transmitted through tick bites, affects approximately 476,000 Americans annually. While most cases resolve with antibiotic treatment, 10–20% of patients develop post-treatment Lyme disease syndrome (PTLDS) — persistent fatigue, cognitive impairment, joint pain, and neurological symptoms lasting months or years after antibiotic therapy. The Lyme community has shown strong interest in HBOT as an adjunct therapy, and it is one of the most commonly sought alternative treatments among chronic Lyme patients.
The rationale for HBOT in Lyme disease is based on several mechanisms. Borrelia burgdorferi is a microaerophilic organism — it thrives in low-oxygen environments. Elevated tissue oxygen from HBOT may create an inhospitable environment for persisting spirochetes. Additionally, HBOT reduces the neuroinflammation associated with Lyme neuroborreliosis, enhances immune function by improving white blood cell oxygen-dependent killing mechanisms, and may help repair damage to myelin sheaths and neural tissue caused by the infection. Many chronic Lyme patients also have impaired microcirculation, which HBOT directly addresses by increasing dissolved plasma oxygen.
Recommended Protocol
Pressure
2.0–2.4 ATA
Sessions
20–40 sessions
Duration
60–90 minutes per session
The evidence for HBOT in Lyme disease is limited but suggestive. A 1998 study by Fife et al. in a small case series showed improvement in symptoms after HBOT at 2.4 ATA. In vitro studies have demonstrated that Borrelia burgdorferi cultures exposed to hyperbaric oxygen show reduced viability. However, no large-scale randomized controlled trials have been conducted specifically for HBOT and Lyme disease. The evidence is largely anecdotal and based on clinical experience, patient reports, and the theoretical mechanism. The International Lyme and Associated Diseases Society (ILADS) acknowledges HBOT as a treatment option that some patients find beneficial, but it is not part of standard treatment guidelines.
Off-Label Use
Lyme Disease is not an FDA-approved indication for HBOT. Treatment is considered off-label and is typically not covered by insurance. Consult your physician before starting any HBOT protocol.
Based on the protocol requirements — minimum 2 ATA, Clinical Grade tier. Sorted by clinical credibility score.

Perry Baromedical
$150,000 - $400,000+

Perry Baromedical
$50,000 - $90,000

Perry Baromedical
$55,000 - $95,000

Perry Baromedical
$65,000 - $110,000

Perry Baromedical
$100,000 - $160,000

Perry Baromedical
$80,000 - $130,000
In vitro studies show that Borrelia burgdorferi cultures are less viable when exposed to hyperbaric oxygen. However, translating this to the human body is more complex — the spirochete can form biofilms and persist in low-oxygen tissue environments. HBOT may help create a less hospitable environment for the bacteria while supporting the immune system's ability to clear it, but it should not be considered a standalone cure.
Many Lyme-literate physicians use HBOT as an adjunct to antibiotic therapy, not a replacement. HBOT may potentiate certain antibiotics (oxygen enhances the bactericidal activity of some antibiotic classes) and may help antibiotics penetrate tissues with impaired circulation. Consult a Lyme-literate physician before combining treatments.
The limited evidence that exists uses 2.0+ ATA. The bacteriostatic effect on Borrelia and the immune-boosting mechanisms require meaningful oxygen elevation beyond what 1.3 ATA provides. For Lyme disease specifically, a clinical-grade chamber at 2.0+ ATA is recommended. Soft-shell chambers may provide some symptom relief (reduced inflammation, improved energy) but are unlikely to address the underlying infection.
Protocols vary widely, but most practitioners use 30–80 sessions. A common starting point is 40 sessions (5 per week for 8 weeks) at 2.0–2.4 ATA, then reassessment. Chronic Lyme patients often require longer courses due to the complex nature of the illness. Dr. William Fife's foundational research at Texas A&M used 1.5–2.4 ATA over multiple courses. Some integrative practitioners use multiple rounds of 20 sessions separated by rest periods to allow the body to process. Unlike wound healing (20–40 sessions) or sports recovery (10–20), Lyme typically requires more aggressive protocols.
This is one of the more promising applications, though still poorly studied in controlled trials. Neurological Lyme causes white matter lesions, reduced cerebral blood flow, and chronic inflammation — all targets of HBOT. SPECT imaging studies have documented improved brain perfusion in Lyme patients after HBOT. Symptoms that patients report improving include brain fog, memory problems, and peripheral neuropathy. However, spirochetes can form biofilms in the CNS that are difficult to eradicate, so HBOT is typically used as part of a comprehensive treatment plan rather than as a standalone cure.
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Use our filterable directory to find chambers that match your protocol requirements.